Merck’s Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%

Merck plans to submit the data on early stage lung cancer to the FDA as soon as possible.

Source: Merck’s Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%